
Biotech At The Crossroads: Trade, War & the Future of Medical Innovation
While GLP-1 drugs and established medtech pulled in billions and shrugged off tariffs, early-stage biotech funding hit a five-year low and neurotech startups were left fighting for scraps. → Political leverage is now a b







